Related Experiment Video
Updated: Jul 19, 2026

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Combined antifungal therapy in a murine infection by Candida glabrata
Marçal Mariné1, Carolina Serena, F Javier Pastor
1Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç 21, 43201, Reus, Spain.
Objectives:
To develop proper treatments for patients who do not respond to current antifungal treatments, we tested new combinations of antifungal drugs for treating disseminated infections by Candida glabrata in a murine model.
Methods:
Mice were rendered neutropenic by intraperitoneal cyclophosphamide and intravenous 5-fluorouracil administration. The animals were infected intravenously with 2 x 10(8) cfu of C. glabrata. The efficacies of micafungin combined with amphotericin B, fluconazole or flucytosine, and of amphotericin B combined with fluconazole were evaluated by survival and tissue burden reduction.
Results And Conclusions:
Micafungin plus amphotericin B was the most effective combination at reducing tissue burden. Micafungin at 10 mg/kg combined with amphotericin B at 0.75, 1.5 or 3 mg/kg prolonged survival with respect to the monotherapies, but only the second combination showed a synergistic effect in reducing fungal load in spleen and kidney. Amphotericin B at 1.5 mg/kg combined with micafungin at 5, 10 or 20 mg/kg reduced tissue burden with respect to the monotherapies, but the effects of the three combinations were very similar. These results suggest that amphotericin B in combination with micafungin is promising for the treatment of disseminated C. glabrata infections.
Insights
New antifungal drug combinations were tested for disseminated Candida glabrata infections. Micafungin plus amphotericin B showed the most promise in reducing fungal burden and improving survival in a murine model.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Disseminated Candida glabrata infections pose a significant therapeutic challenge.
- Current antifungal treatments are often ineffective for non-responsive cases.
Purpose of the Study:
- To evaluate novel antifungal drug combinations for treating disseminated C. glabrata infections.
- To identify effective treatment strategies for drug-resistant fungal infections.
Main Methods:
- A murine model of neutropenia was established using cyclophosphamide and 5-fluorouracil.
- Mice were infected with Candida glabrata, and the efficacy of drug combinations (micafungin with amphotericin B, fluconazole, or flucytosine; amphotericin B with fluconazole) was assessed.
- Survival rates and fungal tissue burden in organs were measured.
Main Results:
- Micafungin combined with amphotericin B demonstrated the greatest efficacy in reducing fungal tissue burden.
- Specific combinations of micafungin and amphotericin B prolonged survival and showed synergistic effects in reducing fungal load in the spleen and kidney.
- Amphotericin B at 1.5 mg/kg combined with varying doses of micafungin effectively reduced tissue burden.
Conclusions:
- Amphotericin B in combination with micafungin is a promising therapeutic strategy for disseminated C. glabrata infections.
- Combination therapy offers improved outcomes compared to monotherapy for resistant fungal infections.
Related Concept Videos
Antifungal Agents
Cryptococcal Meningitis
Candidiasis

